Salt Lake Tribune - Alzheimer's drug goes to final testing

Salt Lake Tribune - Alzheimer's drug goes to final testing: "That performance came despite a 52 percent increase in research and development costs, to $24.3 million. The bulk of that spending was for Flurizan, which the company also announced Tuesday had completed enrollment for Phase 3 testing.
In all, 1,600 patients will participate in an 18-month national study. That trial could be cut back to a year if results are exceptionally positive, after which an application for approval by the Food and Drug Administration could be filed."